Aura Biosciences (NASDAQ:AURA) Rating Reiterated by HC Wainwright

HC Wainwright restated their buy rating on shares of Aura Biosciences (NASDAQ:AURA) in a research note released on Friday, Benzinga reports. HC Wainwright currently has a $21.00 target price on the stock.

AURA has been the subject of a number of other research reports. Lifesci Capital upgraded Aura Biosciences to a strong-buy rating in a report on Monday, September 9th. JMP Securities upped their target price on Aura Biosciences from $19.00 to $23.00 and gave the stock a market outperform rating in a report on Friday.

Aura Biosciences Stock Down 1.0 %

AURA stock opened at $9.97 on Friday. The firm has a market cap of $493.94 million, a price-to-earnings ratio of -5.36 and a beta of 0.35. Aura Biosciences has a twelve month low of $5.99 and a twelve month high of $12.35. The business’s fifty day simple moving average is $8.58 and its two-hundred day simple moving average is $7.87.

Aura Biosciences (NASDAQ:AURA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.04. Research analysts expect that Aura Biosciences will post -1.7 EPS for the current year.

Hedge Funds Weigh In On Aura Biosciences

A number of large investors have recently bought and sold shares of the business. Eventide Asset Management LLC increased its holdings in shares of Aura Biosciences by 91.8% in the 4th quarter. Eventide Asset Management LLC now owns 5,802,682 shares of the company’s stock valued at $51,412,000 after acquiring an additional 2,777,777 shares during the period. Matrix Capital Management Company LP raised its holdings in Aura Biosciences by 29.1% in the fourth quarter. Matrix Capital Management Company LP now owns 6,922,870 shares of the company’s stock worth $61,337,000 after purchasing an additional 1,560,000 shares in the last quarter. Franklin Resources Inc. purchased a new stake in shares of Aura Biosciences during the fourth quarter valued at about $5,317,000. Long Focus Capital Management LLC boosted its holdings in shares of Aura Biosciences by 113.4% in the 2nd quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock valued at $7,992,000 after buying an additional 561,766 shares in the last quarter. Finally, Decheng Capital LLC purchased a new position in shares of Aura Biosciences in the 4th quarter worth approximately $4,568,000. Institutional investors own 96.75% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.